Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
02:11pm, Tuesday, 25'th Nov 2025
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk
12:07pm, Tuesday, 25'th Nov 2025
The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.'s (NASDAQ: SRPT) Cohort 8 of ENDEAVOR (Study 9001-103).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
07:30am, Monday, 24'th Nov 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT)
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
07:30am, Monday, 24'th Nov 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
10:00am, Thursday, 20'th Nov 2025
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are adv
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
10:36am, Monday, 17'th Nov 2025
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
2 Beaten-Down Stocks to Avoid Right Now
09:35am, Saturday, 15'th Nov 2025
Intellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments. Both biotechs have lost market value as a result, but both still seem too risky to cons
Sarepta Shares Jump After FDA Approves Updated Elevidys Label
05:48pm, Friday, 14'th Nov 2025
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock jumped on Friday after the FDA issued a new boxed warning for Elevidys. The updated approval follows recent reports of fatal liver injury in non-ambulat
Market Today: Data Delays, CEO Shifts, M&A and Deals
05:35pm, Friday, 14'th Nov 2025
Guru Stock PicksSteven Cohen has made the following transactions:Reduce in FLR by 57.92%Sold out in TATTAdd in GDEN by 26.14%New position in KEXValueAct Capital
Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information
02:54pm, Friday, 14'th Nov 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for EL
US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries
02:08pm, Friday, 14'th Nov 2025
The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys that includes its most serious safety warning and restricts use of the tre
Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)
01:18am, Wednesday, 05'th Nov 2025
Sarepta Therapeutics, Inc. (NASDAQ: SRPT - Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock traders acquired 22,262 call options on the company. This represents
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
02:51pm, Tuesday, 04'th Nov 2025
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026
01:39pm, Tuesday, 04'th Nov 2025
Sarepta Therapeutics, Inc. faces uncertainty after Elevidys' revenue decline and ESSENCE trial failure, leading to a 25% SRPT stock drop. SRPT's PMO franchise remains its cash engine, but regulatory r
